

1. *Usefulness of coronary fractional flow reserve measurements in guiding clinical decisions in intermediate or equivocal left main coronary stenoses*  
Courtis, J., et al.  
Am J Cardiol, 2009. **103**(7): p. 943-9.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19327420](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19327420)
  
2. *Comparison of long-term efficacy of the paclitaxel-eluting stent versus the bare-metal stent for treatment of unprotected left main coronary artery disease*  
Han, Y., et al.  
Am J Cardiol, 2009. **103**(2): p. 194-8.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19121435](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121435)
  
3. *Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes*  
Tamburino, C., et al.  
Am J Cardiol, 2009. **103**(2): p. 187-93.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19121434](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19121434)
  
4. *Long-term clinical benefit of drug-eluting stents over bare-metal stents in diabetic patients with de novo left main coronary artery disease: results from a real-world multicenter registry*  
Capodanno, D., et al.  
Catheter Cardiovasc Interv, 2009. **73**(3): p. 310-6.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19214964](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19214964)
  
5. *Left main intervention in myocardial infarction*  
Castagna, M.T., M.C. Machado, and J.V. de Oliveira  
Catheter Cardiovasc Interv, 2009.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=20049962](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20049962)
  
6. *Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial*  
Hasegawa, T., et al.  
Catheter Cardiovasc Interv, 2009. **73**(1): p. 34-41.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19214964](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19214964)

n&list\_uids=19089934

7. *Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction*

Lee, M.S., et al.

Catheter Cardiovasc Interv, 2009. **73**(1): p. 15-21.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19089930](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19089930)

8. *Coronary revascularization for patients with unprotected left main coronary artery disease: evidence, guidelines, and judgment! Making clinical decisions in 2009*

Moussa, I.D., S.C. Wong, and T. Feldman

Catheter Cardiovasc Interv, 2009. **74**(3): p. 448-58.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19434750](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19434750)

9. *Primary percutaneous coronary intervention for acute myocardial infarction caused by unprotected left main stem thrombosis*

Prasad, S.B., et al.

Catheter Cardiovasc Interv, 2009. **73**(3): p. 301-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19213083](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19213083)

10. *Early and long-term results of percutaneous coronary intervention for unprotected left main trifurcation disease*

Sheiban, I., et al.

Catheter Cardiovasc Interv, 2009. **73**(1): p. 25-31.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19089932](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19089932)

11. *Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease*

Tamburino, C., et al.

Catheter Cardiovasc Interv, 2009. **73**(3): p. 291-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19214963](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19214963)

12. *Assisted circulation using the TandemHeart during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG*

Vranckx, P., et al.

Catheter Cardiovasc Interv, 2009. **74**(2): p. 302-10.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19360865](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19360865)

13. *Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease*

Capodanno, D., et al.

Circ Cardiovasc Interv, 2009. **2**(4): p. 302-8.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=20031732](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20031732)

14. *Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis*

Park, S.J., et al.

Circ Cardiovasc Interv, 2009. **2**(3): p. 167-77.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=20031713](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20031713)

15. *Percutaneous coronary intervention with stent implantation versus coronary artery bypass surgery for treatment of left main coronary artery disease: is it time to change guidelines?*

Park, S.J. and D.W. Park

Circ Cardiovasc Interv, 2009. **2**(1): p. 59-68.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=20031694](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20031694)

16. *Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis*

Hamilos, M., et al.

Circulation, 2009. **120**(15): p. 1505-12.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19786633](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19786633)

17. *Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents*

Kim, Y.H., et al.

Circulation, 2009. **120**(5): p. 400-7.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19620506](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19620506)

18. *High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease*  
Migliorini, A., et al.  
Circulation, 2009. **120**(22): p. 2214-21.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19917884](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19917884)
  
19. *Surgery, not percutaneous revascularization, is the preferred strategy for patients with significant left main coronary stenosis*  
Smith, C.R.  
Circulation, 2009. **119**(7): p. 1013-20.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19237672](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19237672)
  
20. *Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry*  
Toyofuku, M., et al.  
Circulation, 2009. **120**(19): p. 1866-74.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19858414](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19858414)
  
21. *Unprotected left main stenting in the real world: two-year outcomes of the French left main taxus registry*  
Vaquerizo, B., et al.  
Circulation, 2009. **119**(17): p. 2349-56.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19380624](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19380624)
  
22. *Simultaneous quadruple kissing stenting of an unprotected left main coronary artery*  
Dubois, C.L., P. Kayaert, and W. Desmet  
Eur Heart J, 2009.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19942603](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19942603)
  
23. *Unprotected left main revascularization in patients with acute coronary syndromes*  
Montalescot, G., et al.  
Eur Heart J, 2009. **30**(19): p. 2308-17.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19720640](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19720640)

24. *Ostial and midshaft lesions vs. bifurcation lesions in 1111 patients with unprotected left main coronary artery stenosis treated with drug-eluting stents: results of the survey from the Italian Society of Invasive Cardiology*

Palmerini, T., et al.

Eur Heart J, 2009. **30**(17): p. 2087-94.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19508996](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19508996)

25. *Are drug-eluting stents superior to bare-metal stents in patients with unprotected non-bifurcational left main disease? Insights from a multicentre registry*

Tamburino, C., et al.

Eur Heart J, 2009. **30**(10): p. 1171-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19276194](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19276194)

26. *Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry*

Buszman, P.E., et al.

J Am Coll Cardiol, 2009. **54**(16): p. 1500-11.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19699048](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19699048)

27. *Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards*

Kandzari, D.E., et al.

J Am Coll Cardiol, 2009. **54**(17): p. 1576-88.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19833256](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19833256)

28. *Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry*

Lee, J.Y., et al.

J Am Coll Cardiol, 2009. **54**(9): p. 853-9.

[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19695467](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19695467)

29. *Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease*  
Mehilli, J., et al.  
J Am Coll Cardiol, 2009. **53**(19): p. 1760-8.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19422982](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19422982)
30. *Temporal pattern of ischemic events in relation to dual antiplatelet therapy in patients with unprotected left main coronary artery stenosis undergoing percutaneous coronary intervention*  
Palmerini, T., et al.  
J Am Coll Cardiol, 2009. **53**(14): p. 1176-81.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19341857](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19341857)
31. *Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study)*  
Sheiban, I., et al.  
J Am Coll Cardiol, 2009. **54**(13): p. 1131-6.  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=19761932](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19761932)